R&D News | pharmaphorum

News

Illumina names successor to former CEO de Souza

Illumina has appointed Agilent Technologies executive Jacob Thaysen as its new chief executive, following the departure of former CEO Francis deSouza in June and chairman

News

Tivdak boosts survival in advanced cervical cancer

Seagen and Genmab's antibody-drug conjugate Tivdak has been shown to improve overall survival when used as a second-line monotherapy for recurrent or metastatic cervical c

News

EMA starts review of Italfarmaco's Duchenne drug

Italfarmaco's marketing application for HDAC inhibitor givinostat as a treatment for Duchenne muscular dystrophy (DMD) has been accepted by the EMA, setting up an approval

News

Roche seeks early-stage lung cancer use for Alecensa

Roche plans to file its Alecensa drug for use in early-stage ALK-positive non-small cell lung cancer (NSCLC), potentially making it the first targeted therapy for these pa

News

Ergomed aims to go private via £703m Permira takeover

UK biopharma services company Ergomed will be taken into private hands with a takeover by a subsidiary of investment group Permira that values the company at around £703 m

News

Otsuka makes psychedelics play, buying Mindset

Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.

Illumina names successor to former CEO de Souza

Tivdak boosts survival in advanced cervical cancer

EMA starts review of Italfarmaco's Duchenne drug

Roche seeks early-stage lung cancer use for Alecensa

Ergomed aims to go private via £703m Permira takeover

Otsuka makes psychedelics play, buying Mindset

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks